* known allergy to (components of) the bcg vaccine or serious adverse events in relation to prior bcg administration * previous mycobacterium tuberculosis (m. tuberculosis) infection or known active or latent infection with m. tuberculosis or other mycobacterial species * previous confirmed covid-19 infection * fever (\>38 c) within the past 24 hours or suspicion of active viral or bacterial infection * vaccination with other live attenuated vaccine within the last 4 weeks * severely immunocompromised subjects. this exclusion category comprises: * subjects with known infection with the human immunodeficiency virus (hiv) * subjects with solid organ transplantation or bone marrow transplantation * subjects under chemotherapy * subjects with primary immunodeficiency * treatment with any anti-cytokine therapy within the last year * treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months * active solid or non-solid malignancy or lymphoma within the prior two years * subjects who do not have access to e-boks.

* known allergy to (components of) the bcg vaccine or serious adverse events in relation to prior bcg administration * previous mycobacterium tuberculosis (m. tuberculosis) infection or known active or latent infection with m. tuberculosis or other mycobacterial species * previous confirmed covid-19 infection * fever (\>38 c) within the past 24 hours or suspicion of active viral or bacterial infection * vaccination with other live attenuated vaccine within the last 4 weeks * severely immunocompromised subjects. this exclusion category comprises: * subjects with known infection with the human immunodeficiency virus (hiv) * subjects with solid organ transplantation or bone marrow transplantation * subjects under chemotherapy * subjects with primary immunodeficiency * treatment with any anti-cytokine therapy within the last year * treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months * active solid or non-solid malignancy or lymphoma within the prior two years * subjects who do not have access to e-boks.

- known allergy to (components of) the bcg vaccine or serious adverse events in relation to prior bcg administration - previous mycobacterium tuberculosis (m. tuberculosis) infection or known active or latent infection with m. tuberculosis or other mycobacterial species - previous confirmed covid-19 infection - fever (>38 c) within the past 24 hours or suspicion of active viral or bacterial infection - vaccination with other live attenuated vaccine within the last 4 weeks - severely immunocompromised subjects. this exclusion category comprises: - subjects with known infection with the human immunodeficiency virus (hiv) - subjects with solid organ transplantation or bone marrow transplantation - subjects under chemotherapy - subjects with primary immunodeficiency - treatment with any anti-cytokine therapy within the last year - treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months - active solid or non-solid malignancy or lymphoma within the prior two years - subjects who do not have access to e-boks.

- known allergy to (components of) the bcg vaccine or serious adverse events in relation to prior bcg administration - previous mycobacterium tuberculosis (m. tuberculosis) infection or known active or latent infection with m. tuberculosis or other mycobacterial species - previous confirmed covid-19 infection - fever (>38 c) within the past 24 hours or suspicion of active viral or bacterial infection - vaccination with other live attenuated vaccine within the last 4 weeks - severely immunocompromised subjects. this exclusion category comprises: - subjects with known infection with the human immunodeficiency virus (hiv) - subjects with solid organ transplantation or bone marrow transplantation - subjects under chemotherapy - subjects with primary immunodeficiency - treatment with any anti-cytokine therapy within the last year - treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months - active solid or non-solid malignancy or lymphoma within the prior two years - subjects who do not have access to e-boks.